S'abonner

Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial - 17/08/16

Doi : 10.1016/S1473-3099(16)30054-8 
Milagritos D Tapia, MD a, Samba O Sow, ProfMD b, Boubou Tamboura, PharmD b, Ibrahima Tégueté, MD c, Marcela F Pasetti, ProfPhD a, Mamoudou Kodio, PharmD b, Uma Onwuchekwa, BS b, Sharon M Tennant, PhD a, William C Blackwelder, ProfPhD a, Flanon Coulibaly, MD b, Awa Traoré, PharmD b, Adama Mamby Keita, MD b, Fadima Cheick Haidara, MD b, Fatoumata Diallo, MD b, Moussa Doumbia, MD b, Doh Sanogo, MD b, Ellen DeMatt, MA d, Nicholas H Schluterman, PhD e, Andrea Buchwald, BS e, Karen L Kotloff, ProfMD a, Wilbur H Chen, MD a, Evan W Orenstein, MD f, g, Lauren A V Orenstein, MD f, h, Julie Villanueva, PhD i, Joseph Bresee, MD i, John Treanor, ProfMD j, Myron M Levine, ProfMD a,
a Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA 
b Le Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali 
c Department of Obstetrics and Gynecology, Hôpital Gabriel Touré, Bamako, Mali 
d Cooperative Studies Program Coordinating Center, Department of Veterans Affairs, Perry Point, MD, USA 
e Department of Epidemiology, University of Maryland, Baltimore, MD, USA 
f Emory University School of Medicine, Atlanta, GA, USA 
g Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia PA, USA 
h Department of Dermatology, University of Pennsylvania Hospital, Philadelphia PA, USA 
i National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA 
j Division of Infectious Diseases, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA 

*Correspondence to: Prof Myron M Levine, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USACorrespondence to: Prof Myron M LevineCenter for Vaccine DevelopmentUniversity of Maryland School of MedicineBaltimoreMD21201USA

Summary

Background

Despite the heightened risk of serious influenza during infancy, vaccination is not recommended in infants younger than 6 months. We aimed to assess the safety, immunogenicity, and efficacy of maternal immunisation with trivalent inactivated influenza vaccine for protection of infants against a first episode of laboratory-confirmed influenza.

Methods

We did this prospective, active-controlled, observer-blind, randomised phase 4 trial at six referral centres and community health centres in Bamako, Mali. Third-trimester pregnant women (≥28 weeks’ gestation) were randomly assigned (1:1), via a computer-generated, centre-specific list with alternate block sizes of six or 12, to receive either trivalent inactivated influenza vaccine or quadrivalent meningococcal vaccine. Study personnel administering vaccines were not masked to treatment allocation, but allocation was concealed from clinicians, laboratory personnel, and participants. Infants were visited weekly until age 6 months to detect influenza-like illness; laboratory-confirmed influenza diagnosed with RT-PCR. We assessed two coprimary objectives: vaccine efficacy against laboratory-confirmed influenza in infants born to women immunised any time prepartum (intention-to-treat population), and vaccine efficacy in infants born to women immunised at least 14 days prepartum (per-protocol population). The primary outcome was the occurrence of a first case of laboratory-confirmed influenza by age 6 months. This trial is registered with ClinicalTrials.gov, number NCT01430689.

Findings

We did this trial from Sept 12, 2011, to Jan 28, 2014. Between Sept 12, 2011, and April 18, 2013, we randomly assigned 4193 women to receive trivalent inactivated influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085). There were 4105 livebirths; 1797 (87%) of 2064 infants in the trivalent inactivated influenza vaccine group and 1793 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6 months. We recorded 5279 influenza-like illness episodes in 2789 (68%) infants, of which 131 (2%) episodes were laboratory-confirmed influenza. 129 (98%) cases of laboratory-confirmed influenza were first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent inactivated influenza vaccine group). In the intention-to-treat population, overall infant vaccine efficacy was 33·1% (95% CI 3·7–53·9); in the per-protocol population, vaccine efficacy was 37·3% (7·6–57·8). Vaccine efficacy remained robust during the first 4 months of follow-up (67·9% [95% CI 35·1–85·3] by intention to treat and 70·2% [35·7–87·6] by per protocol), before diminishing during the fifth month (57·3% [30·6–74·4] and 60·7 [33·8–77·5], respectively). Adverse event rates in women and infants were similar among groups. Pain at the injection site was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inactivated influenza vaccine (n=253 vs n=132; p<0·0001), although 354 [92%] reactions were mild. Obstetrical and non-obstetrical serious adverse events were reported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the trivalent inactivated influenza vaccine group. Presumed neonatal infection was more common in infants in the trivalent inactivated influenza vaccine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0·02). No serious adverse events were related to vaccination.

Interpretation

Vaccination of pregnant women with trivalent inactivated influenza vaccine in Mali—a poorly resourced country with high infant mortality—was technically and logistically feasible and protected infants from laboratory-confirmed influenza for 4 months. With adequate financing to procure the vaccine, implementation will parallel the access to antenatal care and immunisation coverage of pregnant women with tetanus toxoid.

Funding

Bill & Melinda Gates Foundation.

Le texte complet de cet article est disponible en PDF.

Plan


© 2016  Tapia et al. Open Access article distributed under the terms of CC BY. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 16 - N° 9

P. 1026-1035 - septembre 2016 Retour au numéro
Article précédent Article précédent
  • Antimicrobial stewardship across 47 South African hospitals: an implementation study
  • Adrian J Brink, Angeliki P Messina, Charles Feldman, Guy A Richards, Piet J Becker, Debra A Goff, Karri A Bauer, Dilip Nathwani, Dena van den Bergh, Netcare Antimicrobial Stewardship Study Alliance *
| Article suivant Article suivant
  • Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial
  • Michael Schwameis, Bernhard Roppenser, Christa Firbas, Corina S Gruener, Nina Model, Norbert Stich, Andreas Roetzer, Nina Buchtele, Bernd Jilma, Martha M Eibl

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.